...as president of Alexza’s Alexza Singapore Pte. Ltd. subsidiary, formerly VP of corporate development at Scion Pharmaceuticals Inc. WIR...

...Xention received rights from Scion to undisclosed ion channel modulators that Scion originally licensed from BMY...
...ED). The most advanced compound has completed Phase I testing. Financial terms were not disclosed. Scion Pharmaceuticals Inc....

...High throughput screening Hired: Barry Berkowitz as president and CEO, formerly president and CEO at Scion Pharmaceuticals Inc....

...a consultant to the company. Previously, Berkowitz was corporate VP at Albany Molecular Research (AMRI). Scion...
...develop small molecules for neurological and cardiovascular indications ( see BioCentury, Jan. 26, 2004 ). Scion's...

...Jeffrey Williams as SVP of corporate and business development, formerly VP of corporate development at Scion Pharmaceuticals Inc. WIR...

...identification. The technique has been most often reserved for more focused lead optimization work. However, Scion Pharmaceuticals Inc....
...But binding assays don't give any information about the cellular response - electrophysiology does. For Scion...
...functional information. They just tell you whether or not you are binding the receptor." Thus, Scion...

...U.S. revenues for anti-epileptic and pain indications, according to Chaturvedi Pravin, president and CEO of Scion Pharmaceuticals Inc....
...NO-steroids and an NO-donating version of gabapentin to treat neuropathic pain, according to Garufi. Meanwhile, Scion...